Intracavitary perfusion of Carboplation and Interferon by implanted pleural catheter for malignant pleural effusion
- VernacularTitle:胸腔内置管化疗在恶性胸腔积液治疗中的作用
- Author:
Li LIANG
;
Liwen MA
;
Shulan ZHANG
- Publication Type:Journal Article
- Keywords:
Malignant pleural effusion Catheter Carboplatin ?-2b Interferon
- From:
Chinese Journal of Minimally Invasive Surgery
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of center vein catheter thoracostomy in the chemotherapy of malignant pleural effusion. Methods Carboplatin and ?-2b Interferon were infused into pleural cavity by implanted center vein catheter in the group observation (n=17). After repeated thoracocentesis, the same drugs were introduced into pleural cavity in the group control (n=29). At the end of the 1st, 3rd and 6th month after drug administration, follow-up was carried out to assess the response rates. Results At the end of the 1st, 3rd and 6th month after intrapleural therapies, the number of intrapleural therapies in the group observation was (2.2?1.9) times and in the group control (5.3?1.3)times, with statistically significant difference between the two groups (t=5.924, P=0.00). Numbers of complete remission (CR) in the group observation was 10 of 16, 11 of 16 and 10 of 15, respectively and in the group control 9 of 29, 11 of 29 and 5 of 19, respectively, producing significant difference (P=0.043, 0.050, 0.020, respectively). Overall response rates in the group observation were 87.5%, 87.5% and 80.0%, respectively, while in control were 62.5%, 68.7% and 66.7%, respectively, without significant difference (P=0.356, 0.114, 0.178, respectively). Compared with the control, long-term follow-up (six months) showed higher response rates in the group observation: 10 of 15 patients remained CR at 6th month after therapies. No significant difference was seen in respect to adverse effects(?2=2.491,P=0.114). Conclusions Intrapleural chemotherapy by center vein catheter may increase CR and decrease application times of Carboplatin and ?-2b Interferon in the treatment of malignant pleural effusion, with fewer side effects.
